Eli Lilly and Boehringer Ingelheim recently celebrated a heart failure FDA label expansion for their SGLT 2 drug, Jardiance, and now a potential rival from Lexicon Pharmaceuticals has suffered a ...
Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food and Drug ...
A Lexicon Pharmaceuticals drug that failed to secure FDA approval in type 1 diabetes under a partnership with Sanofi is now approved as a heart failure therapy. The regulatory nod puts the Lexicon ...
May 26 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's (LXRX.O), opens new tab drug for a broad treatment of heart failure, including in adult ...
(Reuters) -Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, ...
Nov 22 (Reuters) - Lexicon Pharmaceuticals (LXRX.O), opens new tab said on Friday it would reduce its workforce by about 60%, after the U.S. Food and Drug Administration noted deficiencies in its ...
THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback